KHRN.V - Khiron Life Sciences Corp.
| Previous Close | 0.0400 |
| Open | 0.0450 |
| Bid | 0.0350 x 0 |
| Ask | 0.0450 x 0 |
| Day's Range | 0.0400 - 0.0450 |
| 52 Week Range | 0.0350 - 0.2100 |
| Volume | |
| Avg. Volume | 226,937 |
| Market Cap | 9.296M |
| Beta (5Y Monthly) | 3.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings Date | May 29, 2023 - Jun 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.10 |
CNW GroupKHIRON LIFE SCIENCES ANNOUNCES CEASE TRADE ORDER
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) announced today that, further to its press release dated April 17, 2023, the Ontario Securities Commission (the "OSC") has denied the Company's application for a management cease trade order (the "MCTO") in connection with its delay in filing its audited annual financial statements (the "Financial Statements"), management's discussion and analysis ("MD&A") and related Chief Executive Officer and Chief Financial Of
NewsfileMedical First: Germany Strengthens Reimbursement of Medical Cannabis
On 16 March 2023, after five years of observational data collection the German Federal Joint Committee (G-BA) decided on the future regulations that will govern the prescription of medical cannabis as a benefit of the statutory health insuranceAfter several months of discussions and thoroughly analyzing the data, the G-BA passed regulations that ensure patient care with medical cannabis and coverage by statutory health insuranceGermany is the largest and fastest growing medical cannabis market i
NewsfileKhiron Completes First Phase of Business Optimization
First phase of optimization was focused on streamlining Colombian operations, resulting in a moving forward annualized cost reduction of CAD 5.0 million, representing overall cost savings of more than 45% compared to 20221.Khiron has completed the wind down of its Colombian cultivation and extraction activities, to focus on its clinics business and its high-margin B2C medical cannabis model in Colombia.Similar to the Company’s European production model, Khiron Colombia will outsource the product
CNW GroupKHIRON LIFE SCIENCES ANNOUNCES NEW CFO
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased announce that it has appointed Mr. Michael O'Connor as Chief Financial Officer of the Company, replacing the Company's CFO, Ms. Helen Bellwood.
Simply Wall St.Take Care Before Jumping Onto Khiron Life Sciences Corp. (CVE:KHRN) Even Though It's 47% Cheaper
To the annoyance of some shareholders, Khiron Life Sciences Corp. ( CVE:KHRN ) shares are down a considerable 47% in...
NewsfileKhiron Life Sciences Announces Closing of Marketed Offering Including Full Exercise of Over-Allotment Option
Toronto, Ontario--(Newsfile Corp. - April 4, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") is pleased to announce that it has closed today its previously announced marketed public offering of units of the Company ("Units"), including the exercise in full of the over-allotment option (the "Offering").A total of 13,800,000 Units were sold at a price of $0.05 per Unit (the "Offering Price") for aggregate gross proceeds of $690,000. ...
CNW GroupKHIRON LIFE SCIENCES ANNOUNCES SIZING OF MARKETED OFFERING OF UNITS
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce the sizing of its previously announced marketed public offering (the "Offering"). Pursuant to the Offering, the Company will issue up to 12,000,000 units of the Company (each, a "Unit") at a price of C$0.05 per Unit (the "Offering Price") for aggregate gross proceeds of up to C$600,000. Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purc
CNW GroupKHIRON LIFE SCIENCES ANNOUNCES PRICING OF MARKETED OFFERING OF UNITS
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce the pricing of its previously announced marketed public offering (the "Offering"). Pursuant to the Offering, the Company will issue units of the Company (each, a "Unit") at a price of C$0.05 per Unit (the "Offering Price"). Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant of the Company (each, a "Unit Warrant"), with each
CNW GroupKHIRON LIFE SCIENCES ANNOUNCES OVERNIGHT MARKETED OFFERING
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has launched an overnight marketed public offering (the "Offering") of the Company's units (each, a "Unit"). Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant of the Company (each, a "Unit Warrant"), with each Unit Warrant being exercisable to acquire one Common Share (each, a "Warrant Share") for a period of 24 mon
NewsfileKhiron Closes Additional Loan with Investment-Grade Bank
The term loan, provided by one of Colombia's largest and traditional private banks, provides immediate access to liquidity, and further strengthens Khiron's credibility with long-established banking institutions.Toronto, Ontario--(Newsfile Corp. - February 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (WKN: A2JMZC) ("Khiron" or the "Company") , announces that its wholly owned subsidiary Zerenia™ Colombia has closed a credit facility of around CAD 700,000[1] with one of Colom
NewsfileKhiron Closes Revolving Credit Facility with Financing Company in Colombia
Toronto, Ontario--(Newsfile Corp. - February 14, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (FSE: A2JMZC) ("Khiron" or the "Company"), announces that its wholly owned subsidiary ZereniaTM Colombia has closed an unsecured revolving credit facility of CAD 580,0001 with a private financing company in Colombia.The 12-month revolving credit facility became effective on February 10, 2023, and was provided by a Colombian private financing company. The Company was granted this workin
CNW GroupKhiron begins dispensation of insurance-covered prescriptions in Colombia
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that it has begun dispensing medical cannabis to patients in its wholly owned ZereniaTM clinic, under the insurance coverage system approved by the Government of Colombia on January 1st, 2023.
CNW GroupNHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to spearhead the medical cannabis market in the United Kingdom by successfully attaining, for the first time, full reimbursement by the NHS of costs associated to cannabis-based medication and clinic fees for a patient enrolled in Zerenia™ Clinics UK. The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment opti
CNW GroupKhiron wins first medical cannabis contract with Colombia's largest public insurance company
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the medical cannabis market in LATAM by announcing that Zerenia has signed a contract with insurance CAPITAL SALUD EPS, to provide medical cannabis services and products to CAPITAL SALUD EPS patient population and has already begun treating the first cohort of patients. Under the contract, CAPITAL SALUD EPS patients will get access to Khiron's products and clinical service
CNW GroupGovernment of Colombia Declares Mandatory Insurance Coverage for Medical Cannabis Products
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that the new Colombian Government has included plant-based medical cannabis products (i.e., Khiron products) in the list of mandatory insurance-covered medications starting January 1st, 2023, as well as the signing of a first-of-its-kind medical cannabis contract with one of Colombia´s largest insurance companies based in the city of Bogota.
- Simply Wall St.
Khiron Life Sciences Third Quarter 2022 Earnings: CA$0.017 loss per share (vs CA$0.019 loss in 3Q 2021)
Khiron Life Sciences ( CVE:KHRN ) Third Quarter 2022 Results Key Financial Results Revenue: CA$3.39m (down 3.8% from 3Q...
CNW GroupKhiron Life Sciences Reports Third Quarter 2022 Financial Results
Khiron Life Sciences Corp. ("Khiron" or the "Corporation") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announced today its financial results for the quarter ended September 30, 2022, which were prepared in accordance with International Financial Reporting Standards ("IFRS"). Third quarter 2021 comparable numbers were also prepared in accordance with IFRS. All financial results for the third quarter ended September 30,
CNW GroupKhiron to Host Third Quarter 2022 Conference Call on November 30, 2022
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMXC), the global leader in medical cannabis throughout Latin America and Europe, today announces that it will host a Conference Call on November 30, 2022 at 11:00 a.m. eastern time to discuss its results for the third quarter ended September 30, 2022. The Company will press release its financial results prior to the Conference Call. These filings will be available for review on the Company's SEDAR p
CNW GroupKhiron begins sales in Switzerland and expands its medical cannabis portfolio in Germany and the United Kingdom
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces its market entry into Switzerland with initial sales of new products and increases its product offerings in Germany and UK.
CNW GroupKhiron Life Sciences Awarded Best Latin American Cannabis Company at Benzinga Cannabis Capital Conference
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Europe and Latin America, today announced that received the Best Latin American Cannabis Company award at Benzinga's 2022 Cannabis Capital Conference in Chicago.
CNW GroupKhiron, the Global Leader in Medical Cannabis Launches New Cannabis Products in Europe including Stellar Genetics from California
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Europe and Latin America, announces its new medical product portfolio in Europe. The new products, which are already being promoted to prescribers, pharmacies, and patients, will be exclusively distributed through Khiron's wholly-owned Pharmadrug Production GmbH and will be available to pharmacies and patients in Germany and the UK in the coming w
CNW GroupKhiron Life Sciences Reports Second Quarter 2022 Financial Results
Khiron Life Sciences Corp. ("Khiron" or the "Corporation") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical cannabis throughout Latin America and Europe, announced today its financial results for the quarter ended June 30, 2022. These filings are available for review on the Corporation's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
- Simply Wall St.
Is Khiron Life Sciences (CVE:KHRN) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
CNW GroupKhiron to Host Second Quarter 2022 Conference Call on August 29, 2022
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMXC), the global leader in medical cannabis throughout Latin America and Europe, today announces that it will host a Conference Call on Monday, August 29, 2022 at 10:00 a.m. eastern time to discuss its results for the second quarter ended June 30, 2022. The Company will press release its financial results prior to the Conference Call. These filings will be available for review on the Company's SEDAR p